細胞表面マーカーの世界市場予測（～2023年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKET COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DESIGN 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.2 MARKET SIZE ESTIMATION 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 CELL SURFACE MARKERS: MARKET OVERVIEW 30
4.2 CELL SURFACE MARKERS MARKET, BY PRODUCT 31
4.3 CELL SURFACE MARKERS MARKET, BY CELL TYPE (2018) 32
4.4 CELL SURFACE MARKERS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION) 33
4.5 CELL SURFACE MARKERS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 33
4.6 CELL SURFACE MARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increasing funding for life science research 36
5.2.1.2 High global prevalence of cancer 36
5.2.1.3 Growth in stem cell and neurobiology research 37
5.2.2 RESTRAINTS 38
5.2.2.1 Costly and time-intensive antibody development process 38
5.2.3 OPPORTUNITIES 38
5.2.3.1 High growth opportunities in emerging markets 38
6 CELL SURFACE MARKERS MARKET, BY PRODUCT 39
6.1 INTRODUCTION 40
6.2 ANTIBODIES 41
6.2.1 ANTIBODIES TO DOMINATE THE CELL SURFACE MARKER PRODUCTS MARKET DURING THE FORECAST PERIOD 41
6.3 PCR ARRAYS 41
6.3.1 PCR ARRAY PROFILES THE EXPRESSION OF GENES RELEVANT TO RESEARCH AT THE CELL SURFACE MARKER LEVEL 41
7 CELL SURFACE MARKER ANTIBODIES MARKET, BY SOURCE 43
7.1 INTRODUCTION 44
7.2 MICE 45
7.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR RESEARCH-USE CELL SURFACE ANTIBODY PRODUCTION 45
7.3 RATS 45
7.3.1 RATS ARE THE SECOND-MOST-WIDELY USED ANIMAL HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION 45
7.4 OTHER SOURCES 46
8 CELL SURFACE MARKERS MARKET, BY CELL TYPE 47
8.1 INTRODUCTION 48
8.2 T CELL SURFACE MARKERS 49
8.2.1 T CELL SURFACE MARKERS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 49
8.3 B CELL SURFACE MARKERS 49
8.3.1 B CELL SURFACE MARKERS ARE USED TO IDENTIFY B CELLS FROM HETEROGENEOUS SAMPLES 49
8.4 NK CELL SURFACE MARKERS 50
8.4.1 NK CELL SURFACE MARKERS IDENTIFY NK CELLS AT VARIOUS STAGES OF DEVELOPMENT 50
8.5 MONOCYTE CELL SURFACE MARKERS 51
8.5.1 MONOCYTES PLAY A CRITICAL ROLE IN MAINTAINING OVERALL HEALTH 51
8.6 OTHER CELL TYPES 51
9 CELL SURFACE MARKERS MARKET, BY APPLICATION 53
9.1 INTRODUCTION 54
9.2 RESEARCH APPLICATIONS 55
9.2.1 DRUG DISCOVERY 56
9.2.1.1 Cell surface markers play an important role in guiding decisions in every phase of drug development 56
 
9.2.2 IMMUNOLOGY 57
9.2.2.1 The assessment of cell surface antigens using cell surface markers is an important field of immunological research 57
9.2.3 STEM CELL RESEARCH 57
9.2.3.1 Cell surface biomarkers are used to characterize, isolate, and analyze stem cells 57
9.2.4 OTHER RESEARCH APPLICATIONS 58
9.3 CLINICAL APPLICATIONS 59
9.3.1 ONCOLOGY 60
9.3.1.1 Cell surface markers are an emerging diagnostic tool in the field of hematological oncology. 60
9.3.2 IMMUNODEFICIENCY DISEASES 60
9.3.2.1 Cell surface markers are used for the detection of HIV infections 60
9.3.3 OTHER CLINICAL APPLICATIONS 61
10 CELL SURFACE MARKERS MARKET, BY END USER 62
10.1 INTRODUCTION 63
10.2 ACADEMIC & RESEARCH INSTITUTES 64
10.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF THE CELL SURFACE MARKERS MARKET 64
10.3 HOSPITALS & CLINICAL TESTING LABORATORIES 65
10.3.1 HOSPITALS & CLINICAL TESTING LABORATORIES USE CELL SURFACE MARKERS FOR THE DIAGNOSIS OF VARIOUS DISEASES 65
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 65
10.4.1 PATENT EXPIRATION OF BLOCKBUSTER DRUGS TO DRIVE THE GROWTH OF THE CELL MARKERS MARKET FOR THIS END-USER SEGMENT 65
11 CELL SURFACE MARKERS MARKET, BY REGION 67
11.1 INTRODUCTION 68
11.2 NORTH AMERICA 69
11.2.1 US 73
11.2.1.1 High prevalence of chronic diseases 73
11.2.1.2 Favorable funding for precision medicine research activities 73
11.2.2 CANADA 76
11.2.2.1 Availability of research funding 76
11.2.2.2 Increasing prevalence of cancer 76
11.3 EUROPE 79
11.3.1 GERMANY 83
11.3.1.1 Availability of funding driving the number of research activities 83
11.3.1.2 Large-scale outsourcing of clinical diagnostic testing by hospitals to commercial service providers 83
11.3.2 FRANCE 85
11.3.2.1 Presence of a large biotechnology industry 85
11.3.2.2 Government initiatives to boost research and development activities 85
11.3.3 UK 87
11.3.3.1 Government initiatives to strengthen academic research 87
11.3.3.2 Increasing incidence and prevalence of chronic and infectious diseases 88
11.3.4 ROE 90
11.4 ASIA 93
11.5 ROW 98
12 COMPETITIVE LANDSCAPE 103
12.1 OVERVIEW 103
12.2 MARKET RANKING ANALYSIS 104
12.3 COMPETITIVE SCENARIO 105
12.3.1 PARTNERSHIPS AND AGREEMENTS (2016–2018) 105
12.3.2 PRODUCT LAUNCHES (2016–2018) 106
12.3.3 ACQUISITIONS (2016–2018) 106
12.3.4 EXPANSIONS (2016–2018) 106
13 COMPANY PROFILES 108
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 THERMO FISHER SCIENTIFIC 108
13.2 BECTON, DICKINSON AND COMPANY 111
13.3 ABCAM 113
13.4 QIAGEN N.V. 115
13.5 F. HOFFMAN-LA ROCHE 118
13.6 BIO-RAD LABORATORIES 120
13.7 DANAHER CORPORATION 122
13.8 GENSCRIPT 124
13.9 BIOLEGEND 126
13.10 CELL SIGNALING TECHNOLOGY 128
13.11 BIO-TECHNE 129
13.12 MERK KGAA 131

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX 134
14.1 DISCUSSION GUIDE 134
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 137
14.3 AVAILABLE CUSTOMIZATIONS 139
14.4 RELATED REPORTS 139
14.5 AUTHOR DETAILS 140